Sign in

    Thomas...

    Research Analyst at Guggenheim Securities, LLC

    No comprehensive profile for a Thomas working as an analyst at Guggenheim Securities is available based on current public sources. There is no definitive evidence confirming an individual named Thomas holding an analyst or senior analyst title at Guggenheim Securities, and no accessible records of company coverage, performance metrics, or professional credentials under this name and firm. Without a valid LinkedIn profile or other authoritative sources, further details about their specialization, covered companies, track record, or career history cannot be established.

    Thomas...'s questions to MYRIAD GENETICS (MYGN) leadership

    Thomas...'s questions to MYRIAD GENETICS (MYGN) leadership • Q4 2024

    Question

    Thomas..., on behalf of Subbu Nambi, asked about the company's focus for Prolaris amid NCCN guideline confusion and the strategy for GeneSight following recent payer decisions, specifically regarding where management is focusing its efforts.

    Answer

    Chief Commercial Officer Mark Verratti explained that for Prolaris, the focus is on KOL engagement to clear up guideline confusion and increased investment, bolstered by the new PATHOMIQ AI partnership. For GeneSight, he clarified that the sales force remains focused on providers, while the executive team separately handles payer engagement, evidence generation, and advocacy. CEO Paul Diaz added that state biomarker legislation is a key initiative to mitigate the UnitedHealthcare policy change.

    Ask Fintool Equity Research AI